GW Pharma said Sativex, the first cannabis-based drug giving relief to multiple sclerosis sufferers, could be available on prescription by the end of the year. Development costs pushed up half-year pre-tax losses to £7.3m from £5.7m.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in